ArticleApplied biochemistry and biotechnology2026
Preparation and Physicochemical Characterization of Chitosan-Coated Iron Oxide Nanoparticles Conjugated with Oxacillin: Antimicrobial, Antibiofilm, and Biocompatibility Activities against MRSA Staphylococcus aureus.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The growing threat of antimicrobial resistance and biofilm-associated infections has critically undermined the efficacy of conventional antibiotics. Methicillin-resistant Staphylococcus aureus (MRSA) represents a clinically significant multidrug-resistant pathogen renowned for its capacity to form protective biofilms that confer resistance to therapeutic agents. The present study investigated a nanocomposite system comprising chitosan-coated iron oxide nanoparticles conjugated with oxacillin (IONPs-CS-OXA) with the aim of enhancing antimicrobial and antibiofilm efficacy against MRSA. Iron oxide nanoparticles were synthesized via chemical co-precipitation, subsequently coated with chitosan, and conjugated with oxacillin. The nanocomposite was characterized by UV-Vis spectroscopy, FT-IR, XRD, zeta potential analysis, DLS, FE-SEM, and TEM. Multidrug-resistant MRSA isolates obtained from clinical specimens were subjected to antibiotic susceptibility testing, biofilm quantification, minimum inhibitory concentration (MIC) determination, and assessment of antimicrobial and antibiofilm activity. Biocompatibility was evaluated via MTT assays using HdFn and WRL-68 cell lines. Physicochemical characterization confirmed the successful fabrication of spherical IONPs-CS-OXA nanoparticles with nanoscale dimensions and a stable surface charge. MRSA isolates demonstrated high resistance to multiple antibiotics, including oxacillin. The nanocomposite markedly enhanced antimicrobial efficacy, as evidenced by significantly lower MIC values relative to free oxacillin. Inhibition zones were notably enlarged against tested MRSA strains, while biofilm formation was reduced by 54-88%. Cytotoxicity assays confirmed minimal adverse effects on normal cells, with cell viability exceeding 80%. The synergistic interaction among chitosan, iron oxide nanoparticles, and oxacillin conferred enhanced antibacterial and antibiofilm performance alongside acceptable biocompatibility. The IONPs-CS-OXA nanocomposite constitutes a promising candidate platform that, subject to further validation, may augment antibiotic delivery and help combat multidrug-resistant MRSA infections.
Indexed as
Identifiers
42461344What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.